JP6622190B2 - 酵素系含有化粧品組成物 - Google Patents
酵素系含有化粧品組成物 Download PDFInfo
- Publication number
- JP6622190B2 JP6622190B2 JP2016516305A JP2016516305A JP6622190B2 JP 6622190 B2 JP6622190 B2 JP 6622190B2 JP 2016516305 A JP2016516305 A JP 2016516305A JP 2016516305 A JP2016516305 A JP 2016516305A JP 6622190 B2 JP6622190 B2 JP 6622190B2
- Authority
- JP
- Japan
- Prior art keywords
- gram
- composition
- hydrogen peroxide
- concentration
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 630
- 102000004190 Enzymes Human genes 0.000 title claims description 427
- 108090000790 Enzymes Proteins 0.000 title claims description 427
- 239000002537 cosmetic Substances 0.000 title claims description 83
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 758
- 229940088598 enzyme Drugs 0.000 claims description 426
- 108010054320 Lignin peroxidase Proteins 0.000 claims description 330
- 239000000758 substrate Substances 0.000 claims description 202
- 108010015776 Glucose oxidase Proteins 0.000 claims description 127
- 239000004366 Glucose oxidase Substances 0.000 claims description 125
- 229940116332 glucose oxidase Drugs 0.000 claims description 125
- 235000019420 glucose oxidase Nutrition 0.000 claims description 125
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 111
- 239000008103 glucose Substances 0.000 claims description 95
- 238000007254 oxidation reaction Methods 0.000 claims description 88
- 230000003647 oxidation Effects 0.000 claims description 86
- 108010044467 Isoenzymes Proteins 0.000 claims description 45
- 102000004316 Oxidoreductases Human genes 0.000 claims description 30
- 108090000854 Oxidoreductases Proteins 0.000 claims description 30
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 21
- 210000003491 skin Anatomy 0.000 description 160
- 238000000034 method Methods 0.000 description 147
- OEGPRYNGFWGMMV-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanol Chemical group COC1=CC=C(CO)C=C1OC OEGPRYNGFWGMMV-UHFFFAOYSA-N 0.000 description 110
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 86
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 78
- 238000011282 treatment Methods 0.000 description 63
- 239000006071 cream Substances 0.000 description 50
- 239000003795 chemical substances by application Substances 0.000 description 46
- 102000003992 Peroxidases Human genes 0.000 description 44
- OHBQPCCCRFSCAX-UHFFFAOYSA-N 1,4-Dimethoxybenzene Chemical compound COC1=CC=C(OC)C=C1 OHBQPCCCRFSCAX-UHFFFAOYSA-N 0.000 description 42
- 108040007629 peroxidase activity proteins Proteins 0.000 description 39
- 230000000694 effects Effects 0.000 description 38
- 230000001815 facial effect Effects 0.000 description 31
- 230000001590 oxidative effect Effects 0.000 description 30
- 108090000765 processed proteins & peptides Proteins 0.000 description 29
- 229920001184 polypeptide Polymers 0.000 description 26
- 102000004196 processed proteins & peptides Human genes 0.000 description 26
- 230000000699 topical effect Effects 0.000 description 26
- 210000000282 nail Anatomy 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 23
- ABDKAPXRBAPSQN-UHFFFAOYSA-N veratrole Chemical compound COC1=CC=CC=C1OC ABDKAPXRBAPSQN-UHFFFAOYSA-N 0.000 description 23
- 238000009472 formulation Methods 0.000 description 22
- 239000004480 active ingredient Substances 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 21
- 239000013604 expression vector Substances 0.000 description 21
- 239000000839 emulsion Substances 0.000 description 18
- 208000003351 Melanosis Diseases 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 239000012071 phase Substances 0.000 description 17
- 239000003995 emulsifying agent Substances 0.000 description 16
- 229920005610 lignin Polymers 0.000 description 16
- 229920001296 polysiloxane Polymers 0.000 description 16
- 239000002243 precursor Substances 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000008194 pharmaceutical composition Substances 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 239000000463 material Substances 0.000 description 14
- 108091033319 polynucleotide Proteins 0.000 description 14
- 102000040430 polynucleotide Human genes 0.000 description 14
- 239000002157 polynucleotide Substances 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 206010015150 Erythema Diseases 0.000 description 12
- 241000233866 Fungi Species 0.000 description 12
- 208000012641 Pigmentation disease Diseases 0.000 description 12
- 231100000321 erythema Toxicity 0.000 description 12
- 239000006210 lotion Substances 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 11
- 239000013543 active substance Substances 0.000 description 11
- 230000000845 anti-microbial effect Effects 0.000 description 11
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 239000012190 activator Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 230000000007 visual effect Effects 0.000 description 10
- 241000123346 Chrysosporium Species 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 239000003974 emollient agent Substances 0.000 description 9
- -1 glucose hydroquinone compound Chemical class 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 108010025188 Alcohol oxidase Proteins 0.000 description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 8
- 108010023244 Lactoperoxidase Proteins 0.000 description 8
- 102000045576 Lactoperoxidases Human genes 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 229940057428 lactoperoxidase Drugs 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 239000000049 pigment Substances 0.000 description 8
- 108091023020 Aldehyde Oxidase Proteins 0.000 description 7
- 108030000948 Alditol oxidases Proteins 0.000 description 7
- 108010046256 Aryl-alcohol oxidase Proteins 0.000 description 7
- 108030002655 Aryl-aldehyde oxidases Proteins 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 7
- 108010089254 Cholesterol oxidase Proteins 0.000 description 7
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 108010015133 Galactose oxidase Proteins 0.000 description 7
- 108010008292 L-Amino Acid Oxidase Proteins 0.000 description 7
- 102000007070 L-amino-acid oxidase Human genes 0.000 description 7
- 108010090758 L-gulonolactone oxidase Proteins 0.000 description 7
- 108030001003 Long-chain-alcohol oxidases Proteins 0.000 description 7
- 108010063734 Oxalate oxidase Proteins 0.000 description 7
- 108030000946 Paromamine 6'-oxidases Proteins 0.000 description 7
- 108030000947 Prosolanapyrone-II oxidases Proteins 0.000 description 7
- 108030004589 Pyrroloquinoline-quinone synthases Proteins 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 7
- 108030003984 Thiol oxidases Proteins 0.000 description 7
- 108010005214 Vanillyl-alcohol oxidase Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 108010018734 hexose oxidase Proteins 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000002453 shampoo Substances 0.000 description 7
- 102000048262 Aldehyde oxidases Human genes 0.000 description 6
- 108010000659 Choline oxidase Proteins 0.000 description 6
- 206010014970 Ephelides Diseases 0.000 description 6
- 108010001103 Glutathione oxidase Proteins 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 101710086439 Pyranose 2-oxidase Proteins 0.000 description 6
- 108010046017 Pyridoxine 4-oxidase Proteins 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 102100033220 Xanthine oxidase Human genes 0.000 description 6
- 108010093894 Xanthine oxidase Proteins 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 238000005282 brightening Methods 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 108010054790 glycerol-3-phosphate oxidase Proteins 0.000 description 6
- 208000000069 hyperpigmentation Diseases 0.000 description 6
- 230000003810 hyperpigmentation Effects 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 6
- 239000013028 medium composition Substances 0.000 description 6
- 230000036564 melanin content Effects 0.000 description 6
- 230000008099 melanin synthesis Effects 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 230000019612 pigmentation Effects 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 101710105017 2-Hydroxyacid oxidase Proteins 0.000 description 5
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 5
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 5
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 5
- 108010071317 D-arabinonolactone oxidase Proteins 0.000 description 5
- 108010070596 Dihydroorotate Oxidase Proteins 0.000 description 5
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 108010069325 L-glutamate oxidase Proteins 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 102000004722 NADPH Oxidases Human genes 0.000 description 5
- 108010002998 NADPH Oxidases Proteins 0.000 description 5
- 108700020962 Peroxidase Proteins 0.000 description 5
- 102100037209 Peroxisomal N(1)-acetyl-spermine/spermidine oxidase Human genes 0.000 description 5
- 241000723873 Tobacco mosaic virus Species 0.000 description 5
- 108010092464 Urate Oxidase Proteins 0.000 description 5
- 239000002518 antifoaming agent Substances 0.000 description 5
- 239000004599 antimicrobial Substances 0.000 description 5
- 238000004061 bleaching Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 108010020566 glyoxal oxidase Proteins 0.000 description 5
- 239000000118 hair dye Substances 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 108010089000 polyamine oxidase Proteins 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000000153 supplemental effect Effects 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 229940005267 urate oxidase Drugs 0.000 description 5
- 108010033221 veratryl alcohol oxidase Proteins 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 4
- LYRFLYHAGKPMFH-UHFFFAOYSA-N Amide-Octadecanoic acid Natural products CCCCCCCCCCCCCCCCCC(N)=O LYRFLYHAGKPMFH-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 206010008570 Chloasma Diseases 0.000 description 4
- 208000032544 Cicatrix Diseases 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 241000266847 Mephitidae Species 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 206010039580 Scar Diseases 0.000 description 4
- 206010040829 Skin discolouration Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 108700009124 Transcription Initiation Site Proteins 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Chemical compound Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 description 4
- ZCZCOXLLICTZAH-UHFFFAOYSA-N hypothiocyanous acid Chemical compound OSC#N ZCZCOXLLICTZAH-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- 230000037387 scars Effects 0.000 description 4
- 229920002545 silicone oil Polymers 0.000 description 4
- 230000037370 skin discoloration Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- LJCNDNBULVLKSG-UHFFFAOYSA-N 2-aminoacetic acid;butane Chemical compound CCCC.CCCC.NCC(O)=O LJCNDNBULVLKSG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 3
- 108010086710 Hydroxylamine dehydrogenase Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000003212 astringent agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 108010052085 cellobiose-quinone oxidoreductase Proteins 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000012459 cleaning agent Substances 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000001061 forehead Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- AAUNBWYUJICUKP-UHFFFAOYSA-N hypoiodite Chemical compound I[O-] AAUNBWYUJICUKP-UHFFFAOYSA-N 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003138 primary alcohols Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 230000037075 skin appearance Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940037312 stearamide Drugs 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 229940034610 toothpaste Drugs 0.000 description 3
- 239000000606 toothpaste Substances 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 108030001056 (S)-2-hydroxy-acid oxidases Proteins 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100038837 2-Hydroxyacid oxidase 1 Human genes 0.000 description 2
- AHXXIALEMINDAW-UHFFFAOYSA-N 4-(methoxymethyl)phenol Chemical compound COCC1=CC=C(O)C=C1 AHXXIALEMINDAW-UHFFFAOYSA-N 0.000 description 2
- SGNZYJXNUURYCH-UHFFFAOYSA-N 5,6-dihydroxyindole Chemical compound C1=C(O)C(O)=CC2=C1NC=C2 SGNZYJXNUURYCH-UHFFFAOYSA-N 0.000 description 2
- YFTGOBNOJKXZJC-UHFFFAOYSA-N 5,6-dihydroxyindole-2-carboxylic acid Chemical compound OC1=C(O)C=C2NC(C(=O)O)=CC2=C1 YFTGOBNOJKXZJC-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010073997 Bromide peroxidase Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000701489 Cauliflower mosaic virus Species 0.000 description 2
- 108030000979 D-arabinono-1,4-lactone oxidases Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 2
- SXZYCXMUPBBULW-SKNVOMKLSA-N L-gulono-1,4-lactone Chemical compound OC[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O SXZYCXMUPBBULW-SKNVOMKLSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108010059896 Manganese peroxidase Proteins 0.000 description 2
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000222393 Phanerochaete chrysosporium Species 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 108700026226 TATA Box Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 150000001491 aromatic compounds Chemical class 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- RGIBXDHONMXTLI-UHFFFAOYSA-N chavicol Chemical group OC1=CC=C(CC=C)C=C1 RGIBXDHONMXTLI-UHFFFAOYSA-N 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001877 deodorizing effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 210000000883 ear external Anatomy 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical group O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- HLUCICHZHWJHLL-UHFFFAOYSA-N hematein Chemical compound C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- VAMFXQBUQXONLZ-UHFFFAOYSA-N icos-1-ene Chemical compound CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- BVJSUAQZOZWCKN-UHFFFAOYSA-N p-hydroxybenzyl alcohol Chemical compound OCC1=CC=C(O)C=C1 BVJSUAQZOZWCKN-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 108010001816 pyranose oxidase Proteins 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 208000031019 skin pigmentation disease Diseases 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- ZENOXNGFMSCLLL-UHFFFAOYSA-N vanillyl alcohol Chemical compound COC1=CC(CO)=CC=C1O ZENOXNGFMSCLLL-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- MPCAJMNYNOGXPB-SLPGGIOYSA-N 1,5-anhydro-D-glucitol Chemical compound OC[C@H]1OC[C@H](O)[C@@H](O)[C@@H]1O MPCAJMNYNOGXPB-SLPGGIOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- XOQABDOICLHPIS-UHFFFAOYSA-N 1-hydroxy-2,1-benzoxaborole Chemical compound C1=CC=C2B(O)OCC2=C1 XOQABDOICLHPIS-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N 2-hydroxyglutaric acid Chemical compound OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- NJLKZOZYTRRDBO-UHFFFAOYSA-N 3-iodopropyl n-butylcarbamate Chemical compound CCCCNC(=O)OCCCI NJLKZOZYTRRDBO-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- WYVMDJWLFVQZAL-UHFFFAOYSA-N 4-propan-2-ylbenzene-1,2-diol Chemical compound CC(C)C1=CC=C(O)C(O)=C1 WYVMDJWLFVQZAL-UHFFFAOYSA-N 0.000 description 1
- UMYDVEVERVKIFT-UHFFFAOYSA-N 6-(2-amino-2-carboxyethyl)-7,8-dioxo-1,2,3,4,7,8-hexahydroquinoline-2,4-dicarboxylic acid Chemical group O=C1C(=O)C(CC(N)C(O)=O)=CC2=C1NC(C(O)=O)CC2C(O)=O UMYDVEVERVKIFT-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 101100194167 Bacillus subtilis (strain 168) recG gene Proteins 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
- 101100408682 Caenorhabditis elegans pmt-2 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000007458 EC nomenclature Human genes 0.000 description 1
- 108030002503 EC nomenclature Proteins 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108010036012 Iodide peroxidase Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- SXZYCXMUPBBULW-NEEWWZBLSA-N L-galactono-1,4-lactone Chemical compound OC[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@@H]1O SXZYCXMUPBBULW-NEEWWZBLSA-N 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000581002 Murex Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000634333 Mycobacterium bovis AF2122/97 Species 0.000 description 1
- 241000949972 Mycobacterium bovis BCG str. Pasteur 1173P2 Species 0.000 description 1
- 241000823702 Mycobacterium bovis BCG str. Tokyo 172 Species 0.000 description 1
- 241000187492 Mycobacterium marinum Species 0.000 description 1
- 241000385073 Mycobacterium tuberculosis F11 Species 0.000 description 1
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 1
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 1
- 108700035964 Mycobacterium tuberculosis HsaD Proteins 0.000 description 1
- 241001580620 Mycobacterium tuberculosis KZN 1435 Species 0.000 description 1
- 241001414632 Mycobacterium ulcerans Agy99 Species 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- GUNURVWAJRRUAV-UHFFFAOYSA-N N(1)-acetylspermine Chemical compound CC(=O)NCCCNCCCCNCCCN GUNURVWAJRRUAV-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 230000010718 Oxidation Activity Effects 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- JGSMDVGTXBPWIM-UHFFFAOYSA-N Paromamine Natural products OC1C(O)C(N)CC(N)C1OC1C(N)C(O)C(O)C(CO)O1 JGSMDVGTXBPWIM-UHFFFAOYSA-N 0.000 description 1
- 241000212917 Phanerochaete sordida Species 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- 241001085826 Sporotrichum Species 0.000 description 1
- 229920002472 Starch Chemical class 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 102000014267 Thyroid peroxidases Human genes 0.000 description 1
- 241000222355 Trametes versicolor Species 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 1
- HDBIYTHNNXYURA-UHFFFAOYSA-N [O].OOOO Chemical compound [O].OOOO HDBIYTHNNXYURA-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- SXKNCCSPZDCRFD-UHFFFAOYSA-N betaine aldehyde Chemical compound C[N+](C)(C)CC=O SXKNCCSPZDCRFD-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- FYGDTMLNYKFZSV-ZWSAEMDYSA-N cellotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-ZWSAEMDYSA-N 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 244000096108 cunha Species 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- OSSCGHSWPYDTQZ-UHFFFAOYSA-N diazanium hexadecanoate chloride Chemical compound [Cl-].[NH4+].C(CCCCCCCCCCCCC)CC(=O)[O-].[NH4+] OSSCGHSWPYDTQZ-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UFIVEPVSAGBUSI-UHFFFAOYSA-N dihydroorotic acid Chemical compound OC(=O)C1CC(=O)NC(=O)N1 UFIVEPVSAGBUSI-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LVXUNJWLKCUTNF-UHFFFAOYSA-N dimethyl-[3-(octadecanoylamino)propyl]azanium;chloride Chemical compound Cl.CCCCCCCCCCCCCCCCCC(=O)NCCCN(C)C LVXUNJWLKCUTNF-UHFFFAOYSA-N 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000000341 effect on erythema Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 108010062085 ligninase Proteins 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229910001437 manganese ion Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000004972 metal peroxides Chemical class 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 229960000990 monobenzone Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- 239000008385 outer phase Substances 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- JGSMDVGTXBPWIM-HKEUSBCWSA-N paromamine Chemical compound O[C@@H]1[C@@H](O)[C@H](N)C[C@H](N)[C@H]1O[C@@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O1 JGSMDVGTXBPWIM-HKEUSBCWSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FAKIZFXTXMMNRM-JHHIBIJLSA-N prosolanapyrone II Chemical compound COC=1C=C(\C=C\CCCC\C=C\C=C\C)OC(=O)C=1CO FAKIZFXTXMMNRM-JHHIBIJLSA-N 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 210000004511 skin melanocyte Anatomy 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- MWNQXXOSWHCCOZ-UHFFFAOYSA-L sodium;oxido carbonate Chemical compound [Na+].[O-]OC([O-])=O MWNQXXOSWHCCOZ-UHFFFAOYSA-L 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 101150004249 yscJ gene Proteins 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/08—Preparations for bleaching the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Description
リグニンペルオキシダーゼを2.5〜250ユニット/グラムの範囲の濃度で含み、グルコースオキシダーゼを2.5〜250ユニット/グラムの範囲の濃度で含む、第1の組成物と、
D−グルコースを0.35μモル/グラム〜35μモル/グラムの範囲の濃度で含む第2の組成物と
を含む。
本発明は、非限定的に以下の態様を含む。
[態様1]
対象の皮膚および/または毛髪を明るくするための化粧品組成物であって、リグニンペルオキシダーゼ、過酸化水素生成酵素および前記過酸化水素生成酵素の基質を含む、前記化粧品組成物。
[態様2]
前記リグニンペルオキシダーゼの濃度が、1.25ユニット/グラム〜125ユニット/グラムの範囲である、態様1に記載の組成物。
[態様3]
前記過酸化水素生成酵素の濃度が、0.125〜1250ユニット/グラムの範囲である、態様1または2に記載の組成物。
[態様4]
前記過酸化水素生成酵素の前記基質の濃度が、0.0175μモル/グラム〜175μモル/グラムの範囲である、態様1〜3のいずれか1項に記載の組成物。
[態様5]
酸化メディエータをさらに含む、態様1〜4のいずれか1項に記載の組成物。
[態様6]
前記酸化メディエータが、ベラトリルアルコール、ベラトロールおよび1,4−ジメトキシベンゼンから成る群から選択される、態様5に記載の組成物。
[態様7]
前記酸化メディエータの濃度が、0.03μモル/グラム〜300μモル/グラムの範囲である、態様5または6に記載の組成物。
[態様8]
前記過酸化水素生成酵素が、グルコースオキシダーゼ、ヘキソースオキシダーゼ、コレステロールオキシダーゼ、アリールアルコールオキシダーゼ、L−グロノラクトンオキシダーゼ、ガラクトースオキシダーゼ、ピラノース−2−オキシダーゼ、ピリドキシン−4−オキシダーゼ、アルコールオキシダーゼ、2−ヒドロキシ酸オキシダーゼ、コリンオキシダーゼ、長鎖アルコールオキシダーゼ、グリセロール−3−ホスフェートオキシダーゼ、D−アラビノノ−1,4−ラクトンオキシダーゼ、バニリルアルコールオキシダーゼ、アルジトールオキシダーゼ、プロソラナピロンIIオキシダーゼ、パロマミン6’−オキシダーゼ、グリオキサールオキシダーゼ、ベラトリルアルコールオキシダーゼ、アルコールデヒドロゲナーゼ、セロビオースデヒドロゲナーゼ、アルデヒドオキシダーゼ、オキサレートオキシダーゼ、アリールアルデヒドオキシダーゼ、ジヒドロオロテートオキシダーゼ、ピロロキノリン−キノンシンターゼ、L−アミノ酸オキシダーゼ、L−グルタミン酸オキシダーゼ、ポリアミンオキシダーゼ、NAD(P)Hオキシダーゼ、尿酸オキシダーゼ、ヒドロキシルアミンオキシダーゼ、チオールオキシダーゼ、グルタチオンオキシダーゼ、シトクロムcオキシダーゼ、キサンチンオキシダーゼおよびスーパーオキシドジスムターゼから成る群から選択される、態様1〜7のいずれか1項に記載の組成物。
[態様9]
前記過酸化水素生成酵素がグルコースオキシダーゼを含み、前記基質がD−グルコースを含む、態様8に記載の組成物。
[態様10]
前記リグニンペルオキシダーゼが、イソ酵素H1であるかまたはイソ酵素H2の改変体である、態様1〜9のいずれか1項に記載の組成物。
[態様11]
前記リグニンペルオキシダーゼが、白色腐朽菌類のリグニンペルオキシダーゼである態様1〜10のいずれか1項に記載の組成物。
[態様12]
前記リグニンペルオキシダーゼが、ファネロケーテ・クリソスポリウム菌類の抽出物である、態様1〜10のいずれか1項に記載の組成物。
[態様13]
前記化粧品組成物が、マスク、セラム、ローション、クリーム、シャンプー、ゲルおよびトナーから成る群から選択された形態である、態様1〜12のいずれか1項に記載の組成物。
[態様14]
化粧品用として許容される担体をさらに含む、態様1〜13のいずれか1項に記載の組成物。
[態様15]
気密容器に包装される、態様1〜14のいずれか1項に記載の組成物。
[態様16]
対象の皮膚および/または毛髪を明るくするためのキットであって、過酸化水素生成酵素、前記過酸化水素生成酵素の基質、およびリグニンペルオキシダーゼを含み、前記過酸化水素生成酵素、前記過酸化水素生成酵素の前記基質、および前記リグニンペルオキシダーゼの少なくとも1つが、キット内に個別に包装された組成物の一部を形成する、前記キット。
[態様17]
前記過酸化水素生成酵素が第1の組成物の一部を形成し、前記基質が第2の組成物の一部を形成し、前記第1および前記第2の組成物がキット内に個別に包装された、態様16に記載のキット。
[態様18]
前記第1の組成物が、前記リグニンペルオキシダーゼをさらに含む、態様17に記載のキット。
[態様19]
前記第2の組成物が、前記リグニンペルオキシダーゼをさらに含む、態様17に記載のキット。
[態様20]
前記リグニンペルオキシダーゼがキット内の第3の組成物の一部を形成し、前記第3の組成物がキット内で個別に包装された、態様17に記載のキット。
[態様21]
前記過酸化水素生成酵素および前記過酸化水素生成酵素の前記基質が、キット内の気密パッケージ内に一緒に包装された、態様16に記載のキット。
[態様22]
前記リグニンペルオキシダーゼを含む組成物中の前記リグニンペルオキシダーゼの濃度が2.5〜250ユニット/グラムの範囲である、態様16〜21のいずれか1項に記載のキット。
[態様23]
酸化メディエータ、前記過酸化水素生成酵素、前記過酸化水素生成酵素の基質、および前記リグニンペルオキシダーゼを含む、態様16〜22のいずれか1項に記載のキット。
[態様24]
前記酸化メディエータが、前記リグニンペルオキシダーゼを含む組成物の一部を形成する、態様23に記載のキット。
[態様25]
前記酸化メディエータを含む組成物中の前記酸化メディエータの濃度が、0.06μモル/グラム〜600μモル/グラムの範囲である、態様23または24に記載のキット。
[態様26]
前記酵素を含む組成物中の前記過酸化水素生成酵素の濃度が0.25〜2500ユニット/グラムの範囲である、態様16〜25のいずれか1項に記載のキット。
[態様27]
前記基質を含む組成物中の前記基質の濃度が、0.035μモル/グラム〜350μモル/グラムの範囲である、態様16〜26のいずれか1項に記載のキット。
[態様28]
前記過酸化水素生成酵素が、グルコースオキシダーゼ、ヘキソースオキシダーゼ、コレステロールオキシダーゼ、アリールアルコールオキシダーゼ、L−グロノラクトンオキシダーゼ、ガラクトースオキシダーゼ、ピラノース−2−オキシダーゼ、ピリドキシン−4−オキシダーゼ、アルコールオキシダーゼ、2−ヒドロキシ酸オキシダーゼ、コリンオキシダーゼ、長鎖アルコールオキシダーゼ、グリセロール−3−ホスフェートオキシダーゼ、D−アラビノノ−1,4−ラクトンオキシダーゼ、バニリルアルコールオキシダーゼ、アルジトールオキシダーゼ、プロソラナピロンIIオキシダーゼ、パロマミン6’−オキシダーゼ、グリオキサールオキシダーゼ、ベラトリルアルコールオキシダーゼ、アルコールデヒドロゲナーゼ、セロビオースデヒドロゲナーゼ、アルデヒドオキシダーゼ、オキサレートオキシダーゼ、アリールアルデヒドオキシダーゼ、ジヒドロオロテートオキシダーゼ、ピロロキノリン−キノンシンターゼ、L−アミノ酸オキシダーゼ、L−グルタミン酸オキシダーゼ、ポリアミンオキシダーゼ、NAD(P)Hオキシダーゼ、尿酸オキシダーゼ、ヒドロキシルアミンオキシダーゼ、チオールオキシダーゼ、グルタチオンオキシダーゼ、シトクロムcオキシダーゼ、キサンチンオキシダーゼおよびスーパーオキシドジスムターゼから成る群から選択される、態様16〜27のいずれか1項に記載のキット。
[態様29]
前記過酸化水素生成酵素がグルコースオキシダーゼを含み、前記基質がD−グルコースを含む、態様28に記載のキット。
[態様30]
前記リグニンペルオキシダーゼを2.5〜250ユニット/グラムの範囲の濃度で含み、前記グルコースオキシダーゼを2.5〜250ユニット/グラムの範囲の濃度で含む、第1の組成物と、
前記D−グルコースを0.35μモル/グラム〜35μモル/グラムの範囲の濃度で含む第2の組成物と
を含む、態様29に記載のキット
[態様31]
前記リグニンペルオキシダーゼが、イソ酵素H1であるかまたはイソ酵素H2の改変体である、態様16〜30のいずれか1項に記載のキット。
[態様32]
前記リグニンペルオキシダーゼが、白色腐朽菌類のリグニンペルオキシダーゼである態様16〜31のいずれか1項に記載のキット。
[態様33]
前記リグニンペルオキシダーゼが、ファネロケーテ・クリソスポリウム菌類の抽出物である、態様16〜31のいずれか1項に記載のキット。
[態様34]
キット内に個別に包装された前記組成物が、マスク、セラム、ローション、クリーム、シャンプー、ゲルおよびトナーから成る群から選択された形態である、態様16〜33のいずれか1項に記載のキット。
[態様35]
キット内に個別に包装された前記組成物が、化粧品用として許容される担体をさらに含む、態様16〜33のいずれか1項に記載のキット。
[態様36]
対象の皮膚および/または毛髪を明るくする化粧方法であって、対象の皮膚および/または毛髪の領域に、リグニンペルオキシダーゼと、過酸化水素生成酵素と、前記過酸化水素生成酵素の基質とを含む組成物を接触させ、それにより対象の皮膚および/または毛髪を明るくするステップを含む、前記方法。
[態様37]
前記組成物が、化粧品用として許容される担体をさらに含む、態様36に記載の方法。
[態様38]
前記組成物が、態様16〜35のいずれか1項に記載のキット内に包装されたリグニンペルオキシダーゼと、過酸化水素生成酵素と、前記過酸化水素生成酵素の基質とによって形成される、態様36または37に記載の方法。
[態様39]
前記組成物が、態様1〜15のいずれか1項に記載の組成物である、態様36に記載の方法。
[態様40]
前記接触が、少なくとも5回行われる、態様36〜39のいずれか1項に記載の方法。
[態様41]
前記接触が、1日あたり1回または2回行われる、態様36〜40のいずれか1項に記載の方法。
[態様42]
前記皮膚を明るくすることが皮膚の様相全体を明るくすることを含む、態様1〜15のいずれか1項に記載の組成物、態様16〜35のいずれか1項に記載のキット、または態様36〜41のいずれか1項に記載の方法。
[態様43]
前記皮膚が、不均一な皮膚色調、褐色斑、そばかす、黒皮症、色素沈着過剰、皮膚変色、老人性色素斑、にきび痕および/または傷跡を含む、態様1〜15のいずれか1項に記載の組成物、態様16〜35のいずれか1項に記載のキット、または態様36〜41のいずれか1項に記載の方法。
[態様44]
対象の皮膚、毛髪および/または爪に適用するための化粧品または医薬組成物であって、過酸化水素生成酵素および前記過酸化水素生成酵素の基質を含む、前記組成物。
[態様45]
過酸化水素の存在下で化粧品活性または医薬活性を示す少なくとも1種の作用物質をさらに含む、態様44に記載の組成物。
[態様46]
対象の皮膚、毛髪および/または爪に化粧品または医薬組成物を適用するためのキットであって、前記化粧品または医薬組成物が過酸化水素を含み、前記キットが過酸化水素生成酵素を含む第1の組成物と前記過酸化水素生成酵素の基質を含む第2の組成物とを含む、前記キット。
[態様47]
過酸化水素の存在下で化粧品活性または医薬活性を示す少なくとも1種の作用物質をさらに含む、態様46に記載のキット。
[態様48]
対象の皮膚、毛髪および/または爪に過酸化水素を投与する方法であって、対象の皮膚、毛髪および/または爪の領域に、過酸化水素生成酵素と前記過酸化水素生成酵素の基質とを含む組成物を接触させ、それにより皮膚、毛髪および/または爪上で過酸化水素を生成するステップを含む、前記方法。
[態様49]
前記組成物が、態様46または47に記載のキット内に包装された過酸化水素生成酵素と前記過酸化水素生成酵素の基質とによって形成される、態様48に記載の方法。
[態様50]
前記組成物が、態様44または45に記載の組成物である、態様48に記載の方法。
本明細書を通して使用されるとき、語句「過酸化水素生成酵素」は、過酸化水素が生成物となる反応を触媒する酵素を指す。
EC1.1.3オキシドリダクターゼ、例えば、グルコースオキシダーゼ(EC1.1.3.4)、ヘキソースオキシダーゼ(EC1.1.3.5)、コレステロールオキシダーゼ(EC1.1.3.6)、アリールアルコールオキシダーゼ(EC1.1.3.7)、L−グロノラクトンオキシダーゼ(EC1.1.3.8)、ガラクトースオキシダーゼ(EC1.1.3.9)、ピラノース−2−オキシダーゼ(EC1.1.3.10)、ピリドキシン−4−オキシダーゼ(EC1.1.3.12)、アルコールオキシダーゼ(EC1.1.3.13)、2−ヒドロキシ酸オキシダーゼ(EC1.1.3.15)、コリンオキシダーゼ(EC1.1.3.17)、長鎖アルコールオキシダーゼ(EC1.1.3.20)、グリセロール−3−ホスフェートオキシダーゼ(EC1.1.3.21)、D−アラビノノ−1,4−ラクトンオキシダーゼ(EC1.1.3.37)、バニリルアルコールオキシダーゼ(EC1.1.3.38)、アルジトールオキシダーゼ(EC1.1.3.41)、プロソラナピロンIIオキシダーゼ(EC1.1.3.42)、パロマミン6’−オキシダーゼ(EC1.1.3.43)、グリオキサールオキシダーゼおよびベラトリルアルコールオキシダーゼ;
アルコールデヒドロゲナーゼ(EC1.1.99.8);
セロビオースデヒドロゲナーゼ(EC1.1.99.18);
EC1.2.3オキシドリダクターゼ、例えば、アルデヒドオキシダーゼ(EC1.2.3.1)、オキサレートオキシダーゼ(EC1.2.3.4)、およびアリールアルデヒドオキシダーゼ(EC1.2.3.9)など;
EC1.3.3オキシドリダクターゼ、例えば、ジヒドロオロテートオキシダーゼ(EC1.3.3.1)およびピロロキノリン−キノンシンターゼ(EC1.3.3.11);
EC1.4.3オキシドリダクターゼ、例えば、L−アミノ酸オキシダーゼ(EC1.4.3.2)、L−グルタミン酸オキシダーゼ(1.4.3.11);
EC1.5.3オキシドリダクターゼ、例えば、ポリアミンオキシダーゼ(1.5.3.11);
EC1.6.3オキシドリダクターゼ、例えば、NAD(P)Hオキシダーゼ(1.6.3.1);
EC1.7.3オキシドリダクターゼ、例えば、尿酸オキシダーゼ(EC1.7.3.3)、およびヒドロキシルアミンオキシダーゼ(EC1.7.3.4);
EC1.8.3オキシドリダクターゼ、例えば、チオールオキシダーゼ(EC1.8.3.2)およびグルタチオンオキシダーゼ(EC1.8.3.3);
EC1.9.3オキシドリダクターゼ、例えば、シトクロムcオキシダーゼ(EC1.9.3.1);
EC1.17.3オキシドリダクターゼ、例えば、キサンチンオキシダーゼ(EC1.17.3.2);ならびに、
スーパーオキシドジスムターゼ(EC1.15.1.1)。
本明細書に記載の過酸化水素生成組成物は、過酸化水素生成酵素とその基質が酸素(もしくは空気)および/または水の存在下で互いに接触するとき常に過酸化水素を生成する。
そのような組成物に関係するいずれか1つの実施形態による過酸化水素生成組成物は、そのようなキットに関連して本明細書に記載のいずれか1つの実施形態によるキット(例えば、このセクションに記載のキット)を使用して得ることができる。当業者は、本明細書で提供される手引きに基づいて、本明細書に記載の任意の所望の組成物を得るために本明細書に記載の適切なキットを選択することができる。
本明細書に例証されるように、過酸化水素生成酵素をその基質と接触させることによって、本明細書に記載の組成物は、表面への過酸化水素の投与に有効である。
本明細書に記載の組成物、方法およびキットの例示的な実施形態は、局所的身体部位、例えば、皮膚および/または毛髪を明るくするための組成物であって、本明細書に記載の過酸化水素生成組成物をリグニンペルオキシダーゼと組み合わせて使用する組成物である。
リグニンペルオキシダーゼに関連して本明細書に記載のいずれか1つの実施形態によるリグニンペルオキシダーゼ(例えば、このセクションに記載のリグニンペルオキシダーゼ)は、過酸化水素生成酵素系に関して本明細書に記載のいずれか1つの実施形態に従って過酸化水素生成酵素系と組み合わせて使用することができると理解される。
本発明のいくつかの実施形態で(例えば、本明細書に記載のリグニンペルオキシダーゼまたは過酸化水素生成酵素の発現のために)使用される核酸構築物(本明細書で「発現ベクター」とも称される)は、このベクターを原核生物、真核生物、または好ましくは両方(例えば、シャトルベクター)中での複製および統合に適したものにするための追加的配列を含む。さらに、典型的なクローニングベクターは、転写および翻訳開始配列、転写および翻訳ターミネーター、およびポリアデニル化シグナルを含む。例として、そのような構築物は、通常、5’LTR、tRNA結合部位、パッケージングシグナル、第二鎖DNA合成の起点および3’LTRまたはその一部を含む。
本発明のいくつかの実施形態の別の態様によれば、対象の皮膚および/または毛髪などの局所的身体部位を(例えば、本明細書に記載の方法に従って)明るくするためのキットが提供される。キットは、リグニンペルオキシダーゼ(例えば、本明細書に記載のリグニンペルオキシダーゼ)、過酸化水素生成酵素(例えば、本明細書に記載の過酸化水素生成酵素)、および過酸化水素生成酵素の基質(例えば、本明細書に記載の基質)を含む。リグニンペルオキシダーゼ、過酸化水素生成酵素およびその基質の少なくとも1つは、キット内に個別に包装される組成物の一部を形成する。
そのような実施形態において、第1の組成物は、2つの活性酵素を含むことから、「酵素」製剤(例えば、「酵素クリーム」)とも称される。第2の組成物は、リグニンペルオキシダーゼ含有第1組成物と接触したときにリグニンペルオキシダーゼの活性化をもたらすことから、「活性剤」とも称される。
本明細書に記載の発明のいずれかの実施形態およびいずれかの態様のいくつかの実施形態によれば、本明細書に記載の有効成分(例えば、過酸化水素の存在下で活性を示す作用物質、リグニンペルオキシダーゼ、過酸化水素生成酵素、過酸化水素生成酵素の基質および/または酸化メディエータ)は、有効成分自体を含む組成物として使用してもよく、追加的化学成分、例えば、生理学的に適切な担体および賦形剤と組み合わせて使用してもよい。組成物は、本明細書に記載の化粧品または医薬組成物(本明細書に記載の化粧品活性または医薬活性を示す組成物)、ならびに本明細書に記載の化粧品または医薬組成物を調製するために使用されうる(それ自体は不活性でもよい)キット内の組成物(例えば、本明細書に記載の第1の組成物、第2の組成物、および/または第3の組成物)を含む。
材料:
グルコースオキシダーゼ(安定剤は含まず)はSigma−Aldrichから得た。
ベラトリルアルコールはFlukaから得た。
例示的製剤を2つの補足クリームの形態で調製した:1つは、25ユニット/グラムのLIPイソ酵素H1画分と25ユニット/グラムのGOXと0.10重量%のベラトリルアルコール(6mmol/kgクリーム)とを含む酵素クリームであり、もう1つは、グルコース(3.5mmol/kgクリーム)を含む補足活性剤クリームである。
視覚的評価スケール(VAS)は、連続する値の範囲に及び、直接測定することが難しいと考えられる特性または属性を測定するために使用される方法である。VASは水平線として表し、下記のように、各端を用語記述子で固定した。スケールの端は、値0(最も望ましい結果について)および10(最も望ましくない結果について)によって標識した。統計的有意性は反復測定ANOVAに従ってp値を計算することによって決定した。VASを使用して以下の変数をそれぞれ評価した:
色素沈着の一様性(記述子「一様、均一」および「「不均一、シミが多い、まだら」で特定、
透明感(記述子「透明、均一」および「くすみ、不透明」で特定)、
明るさ/鮮やかさ(記述子「明るい/鮮やかな外観」および「くすみ、艶なし」で特定)、
皮膚色調(記述子「均一、健康的な皮膚の色」および「不均一、色褪せた外観」で特定)、
輝き(記述子「輝き、光沢のある外観」および「くすみ、艶なし、血色の悪い外観」で特定)、ならびに
全体的外観(記述子「健康的な外観」および「不健康な外観」で特定)。
処置された対象の顔のデジタル写真撮影を、VISIA(登録商標)−CRフェイシャルイメージングシステムを使用して行い、安定および一貫した周囲照明の環境下に置いた。システムは、各対象による様々な訪問において同じ位置/方向に維持した。
クリーム製剤におけるリグニンペルオキシダーゼ、グルコースオキシダーゼおよびグルコースによるメラニンの酸化
リグニンペルオキシダーゼ(LIP)の酵素源による過酸化水素の活性化における皮膚を明るくする能力を評価するために、LIP、ベラトリルアルコールおよびGOX(グルコースオキシダーゼ)を含む酵素クリーム、ならびにグルコースを含む活性剤クリームを、上記のように調製し、可溶化されたメラニンに対して試験した。結果は、上記に記載したように調製された、LIPおよびベラトリルアルコールを含む酵素クリームから得られた結果、および過酸化水素を含む活性剤クリームから得られた結果と比較した。
リグニンペルオキシダーゼ、グルコースオキシダーゼおよびグルコース含有クリーム製剤で21日間の処置により皮膚を明るくすること
本明細書に記載の例示的な酵素および活性剤クリームについて、in vivoで皮膚を明るくするそれらの能力に関して試験した。
朝
ステップ1 − ELURE(商標)洗顔料
ステップ2 − リグニンペルオキシダーゼおよびグルコースオキシダーゼを含むクリーム(材料と方法のセクションで記載したクリーム)
ステップ3 − グルコースを含む活性剤クリーム(材料と方法のセクションに記載のクリーム)
ステップ4 − SPF30の日焼け止め剤(新たなメラニンの形成を抑制するため)
夜
ステップ1 − 洗顔料
ステップ2 − リグニンペルオキシダーゼおよびグルコースオキシダーゼを含むクリーム
ステップ3 − グルコースを含む活性剤クリーム
リグニンペルオキシダーゼおよびグルコースオキシダーゼを含むクリームを塗布し、皮膚に吸収させた後、活性剤クリームを塗布した。
リグニンペルオキシダーゼ、グルコースオキシダーゼおよびグルコース含有クリーム製剤で8週間処置により皮膚を明るくすること
実施例2に記載した製剤および連日の投与計画を、顕在するが軽度の肝斑などのびまん性色素沈着過剰を有する28人のボランティアの女性対象(33〜50歳)に8週間試験した。次の基準のいずれかを満たす対象は除外した:敏感肌、超敏感肌またはアトピー肌;化粧品または皮膚洗浄剤に対するアレルギー歴;試験の結果に干渉する可能性のある疾患/状態の経歴または進行中の病気;妊娠、妊娠予定または授乳中;試験領域の皮膚障害、例えば、皮膚疾患、あざ、にきび、赤色斑、毛細管拡張症;過去3ヶ月以内の干渉する可能性のある皮膚科医による処置または手法;過去3ヶ月以内の任意の臨床的スキンケア試験に目下関与または参加;この臨床試験への登録に適さないとの内科医による判断。
1)Mexameter(登録商標)皮膚比色計を使用した機器測定、
2)皮膚科医による視覚的評価スケール(VAS)評価、
3)VISIA(登録商標)−CR facial imaging systemを用いたデジタル写真、および
4)対象による自己評価。
Claims (8)
- 対象の皮膚を明るくするための化粧品組成物であって、該組成物はリグニンペルオキシダーゼ、過酸化水素生成酵素および前記過酸化水素生成酵素の基質を含む、ここにおいて、前記過酸化水素生成酵素はグルコースオキシダーゼを含み、前記基質がD−グルコースを含み、そして、前記グルコースオキシダーゼの濃度は、1.25〜125ユニット/グラムの範囲あり、前記D−グルコースの濃度は、0.175μモル/グラム〜17.5μモル/グラムの範囲である、前記化粧品組成物。
- 前記リグニンペルオキシダーゼは、イソ酵素H1であるかまたはイソ酵素H2の改変体である、請求項1に記載の化粧品組成物。
- 前記リグニンペルオキシダーゼの濃度が、1.25ユニット/グラム〜125ユニット/グラムの範囲である、請求項1または2に記載の組成物。
- 酸化メディエータをさらに含む、請求項1〜3のいずれか1項に記載の組成物。
- 対象の皮膚を明るくするためのキットであって、該キットが過酸化水素生成酵素、前記過酸化水素生成酵素の基質、およびリグニンペルオキシダーゼを含み、ここにおいて、前記過酸化水素生成酵素はグルコースオキシダーゼを含み、前記基質がD−グルコースを含み、ここにおいて、前記過酸化水素生成酵素は、第1の組成物の一部を形成し、前記基質は、第2の組成物の一部を形成し、そして、前記第1および第2の組成物はキット内に個別に包装され、そして、ここにおいて、前記第1組成物中の前記グルコースオキシダーゼの濃度は、2.5〜250ユニット/グラムの範囲であり、前記第2組成物中の前記D−グルコースの濃度は、を0.35μモル/グラム〜35μモル/グラムの範囲である、前記キット。
- 前記リグニンペルオキシダーゼは、イソ酵素H1であるかまたはイソ酵素H2の改変体である、請求項5に記載のキット。
- リグニンペルオキシダーゼを含む組成物中の前記リグニンペルオキシダーゼの濃度は、2.5〜250ユニット/グラムの範囲である、請求項5または6のいずれか1項に記載のキット。
- 酸化メディエータをさらに含む、請求項5−7のいずれか1項に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361827685P | 2013-05-27 | 2013-05-27 | |
US61/827,685 | 2013-05-27 | ||
PCT/IL2014/050477 WO2014191995A2 (en) | 2013-05-27 | 2014-05-27 | Enzymatic system-containing cosmetic compositions |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019210232A Division JP6843946B2 (ja) | 2013-05-27 | 2019-11-21 | 酵素系含有化粧品組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016520121A JP2016520121A (ja) | 2016-07-11 |
JP2016520121A5 JP2016520121A5 (ja) | 2017-07-06 |
JP6622190B2 true JP6622190B2 (ja) | 2019-12-18 |
Family
ID=50982944
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016516305A Expired - Fee Related JP6622190B2 (ja) | 2013-05-27 | 2014-05-27 | 酵素系含有化粧品組成物 |
JP2019210232A Active JP6843946B2 (ja) | 2013-05-27 | 2019-11-21 | 酵素系含有化粧品組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019210232A Active JP6843946B2 (ja) | 2013-05-27 | 2019-11-21 | 酵素系含有化粧品組成物 |
Country Status (16)
Country | Link |
---|---|
US (2) | US10980730B2 (ja) |
EP (2) | EP3626310A1 (ja) |
JP (2) | JP6622190B2 (ja) |
KR (1) | KR102280377B1 (ja) |
CN (2) | CN108524320A (ja) |
BR (1) | BR112015029815B1 (ja) |
CA (1) | CA2912997C (ja) |
DK (1) | DK3003493T3 (ja) |
ES (1) | ES2771048T3 (ja) |
HK (1) | HK1222364A1 (ja) |
HR (1) | HRP20192284T1 (ja) |
IL (1) | IL242806B (ja) |
MX (2) | MX368498B (ja) |
RU (1) | RU2015151047A (ja) |
SG (1) | SG11201509636XA (ja) |
WO (1) | WO2014191995A2 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3626310A1 (en) | 2013-05-27 | 2020-03-25 | Rakuto Bio Technologies Ltd. | Enzymatic system containing cosmetic compositions |
DK3389620T3 (da) * | 2015-12-15 | 2022-12-19 | Medicell Tech Llc | Stamcellestimulerende sammensætninger og fremgangsmåder til behandling af melasma |
CN106222159B (zh) * | 2016-08-16 | 2020-03-20 | 绵阳抱朴生物技术有限公司 | 一种抗衰老共固定化酶及其制备方法 |
CN106860032B (zh) * | 2016-10-25 | 2021-04-09 | 咏达生医材料股份有限公司 | 一种气态皮肤供氧美白产品及其应用 |
JP2019194162A (ja) * | 2018-05-01 | 2019-11-07 | ツァ ギャリー | 肌の酸素供給による美白及び加熱機能を備えた通気性材料 |
KR102223091B1 (ko) * | 2019-05-22 | 2021-03-04 | 울산과학기술원 | 리그닌 과산화효소를 포함하는 피부 미백용 화장료 조성물 및 이를 이용한 피부 내 멜라닌의 탈색 방법 |
JP7421695B2 (ja) * | 2019-09-26 | 2024-01-25 | 株式会社ファンケル | メラニン産生抑制剤及びこれを含有する美白剤又は皮膚外用剤 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3155591A (en) | 1961-12-06 | 1964-11-03 | Witco Chemical Corp | Hair rinse compostions of polyoxypropylene quaternary ammonium compounds |
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3755560A (en) | 1971-06-30 | 1973-08-28 | Dow Chemical Co | Nongreasy cosmetic lotions |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3959461A (en) | 1974-05-28 | 1976-05-25 | The United States Of America As Represented By The Secretary Of Agriculture | Hair cream rinse formulations containing quaternary ammonium salts |
DE2437090A1 (de) | 1974-08-01 | 1976-02-19 | Hoechst Ag | Reinigungsmittel |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4387090A (en) | 1980-12-22 | 1983-06-07 | The Procter & Gamble Company | Hair conditioning compositions |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US4421769A (en) | 1981-09-29 | 1983-12-20 | The Procter & Gamble Company | Skin conditioning composition |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5151210A (en) | 1985-07-25 | 1992-09-29 | The Procter & Gamble Company | Shampoo compositions |
DK501686A (da) | 1986-10-20 | 1988-04-21 | Otto Melchior Poulsen | Enzymholdigt, baktericidt middel samt tandplejemidler og saarbehandlingsmidler, som indeholder det |
US5151209A (en) | 1987-11-19 | 1992-09-29 | The Procter & Gamble Company | Shampoo compositions |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5200338A (en) | 1988-11-30 | 1993-04-06 | Idaho Research Foundation, Incorporation | Bacterial extracellular lignin peroxidase |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5011681A (en) | 1989-10-11 | 1991-04-30 | Richardson-Vicks, Inc. | Facial cleansing compositions |
GB9002422D0 (en) | 1990-02-03 | 1990-04-04 | Boots Co Plc | Anti-microbial compositions |
US5120532A (en) | 1990-04-06 | 1992-06-09 | The Procter & Gamble Company | Hair styling shampoos |
US5073371A (en) | 1990-11-30 | 1991-12-17 | Richardson-Vicks, Inc. | Leave-on facial emulsion compositions |
US5073372A (en) | 1990-11-30 | 1991-12-17 | Richardson-Vicks, Inc. | Leave-on facial emulsion compositions |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
US5541110A (en) | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
JP2000506490A (ja) * | 1995-08-18 | 2000-05-30 | ノボ ノルディスク アクティーゼルスカブ | 歯の漂白 |
FR2769220B1 (fr) * | 1997-10-03 | 2000-03-10 | Oreal | Composition oxydante et utilisations pour la teinture, pour la deformation permanente ou pour la decoloration des fibres keratiniques |
FR2794022B1 (fr) | 1999-05-28 | 2001-07-20 | Oreal | Composition de teinture d'oxydation des fibres keratiniques et procede de teinture mettant en oeuvre cette composition |
US6214339B1 (en) | 2000-01-12 | 2001-04-10 | Michael A. Pellico | Di-enzymatic treatment of outer ear infection in dogs and cats |
US20050013784A1 (en) | 2001-02-08 | 2005-01-20 | The Procter & Gamble Company | Mask composition |
KR101168741B1 (ko) * | 2002-12-12 | 2012-07-27 | 알.비.티 (라쿠토 바이오 테크놀로지스) 리미티드 | 리그닌 퍼옥시다제의 제조 방법 및 피부와 모발라이트닝에서의 이의 용도 |
EP2338896B1 (en) * | 2002-12-12 | 2015-02-11 | R.B.T. (Rakuto Bio Technologies) Ltd. | Use of lignin peroxidase in skin and hair lightening |
US20040161435A1 (en) | 2003-02-14 | 2004-08-19 | Gupta Shyam K. | Skin Firming Anti-Aging Cosmetic Mask Compositions |
DE102004029475A1 (de) * | 2004-06-18 | 2006-01-26 | Henkel Kgaa | Neues enzymatisches Bleichsystem |
DE102005041443A1 (de) * | 2005-08-31 | 2007-03-01 | Henkel Kgaa | Mittel zum Färben und/oder Aufhellen keratinischer Fasern mit nanoskaligen Wirkstoffen |
CN101316576B (zh) | 2005-10-21 | 2013-03-27 | 杜邦营养生物科学有限公司 | 含有偶联的酶系统的组合物 |
FR2902004A1 (fr) | 2006-04-14 | 2007-12-14 | Lvmh Rech | Composition cosmetique de type masque pour le soin de la peau |
DE102006042075A1 (de) * | 2006-09-05 | 2008-03-06 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
GB0619786D0 (en) | 2006-10-06 | 2006-11-15 | Inst Of Technology Sligo | An antimicrobial and immunostimulatory system |
DE102006060150A1 (de) * | 2006-12-18 | 2008-06-19 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
US20090241242A1 (en) | 2008-03-31 | 2009-10-01 | Heidi Beatty | Facial mask |
DE102008022710A1 (de) | 2008-05-07 | 2009-11-12 | Henkel Ag & Co. Kgaa | Aufhellmittel mit kationischen Acylpyridiniumderivaten, Co-Bleichaktivatoren und Wasserstoffperoxid |
FR2939654B1 (fr) | 2008-12-12 | 2011-02-11 | Oreal | Procede de coloration capillaire mettant en oeuvre un derive de l'hematoxyline, de l'hemateine, de la braziline ou de la brazileine, un sel metallique, du peroxyde d'hydrogene et du (bi)carbonate |
CA2747056A1 (en) | 2008-12-19 | 2010-07-15 | Novozymes, Inc. | Methods for increasing enzymatic hydrolysis of cellulosic material in the presence of a peroxidase |
DE102009045798A1 (de) * | 2009-10-19 | 2010-08-05 | Henkel Ag & Co. Kgaa | Enzymatische Hautaufhellung |
WO2012153336A2 (en) | 2011-05-12 | 2012-11-15 | Rakuto Bio Technologies Ltd. | Methods and device for lightening skin complexion |
EP3626310A1 (en) | 2013-05-27 | 2020-03-25 | Rakuto Bio Technologies Ltd. | Enzymatic system containing cosmetic compositions |
-
2014
- 2014-05-27 EP EP19199329.4A patent/EP3626310A1/en not_active Withdrawn
- 2014-05-27 MX MX2015016262A patent/MX368498B/es active IP Right Grant
- 2014-05-27 EP EP14732644.1A patent/EP3003493B1/en active Active
- 2014-05-27 RU RU2015151047A patent/RU2015151047A/ru not_active Application Discontinuation
- 2014-05-27 CN CN201810767537.9A patent/CN108524320A/zh active Pending
- 2014-05-27 ES ES14732644T patent/ES2771048T3/es active Active
- 2014-05-27 US US14/894,355 patent/US10980730B2/en active Active
- 2014-05-27 CN CN201480037484.5A patent/CN105407867A/zh active Pending
- 2014-05-27 JP JP2016516305A patent/JP6622190B2/ja not_active Expired - Fee Related
- 2014-05-27 WO PCT/IL2014/050477 patent/WO2014191995A2/en active Application Filing
- 2014-05-27 DK DK14732644.1T patent/DK3003493T3/da active
- 2014-05-27 BR BR112015029815-0A patent/BR112015029815B1/pt not_active IP Right Cessation
- 2014-05-27 CA CA2912997A patent/CA2912997C/en active Active
- 2014-05-27 KR KR1020157036644A patent/KR102280377B1/ko active IP Right Grant
- 2014-05-27 SG SG11201509636XA patent/SG11201509636XA/en unknown
-
2015
- 2015-11-25 MX MX2019011933A patent/MX2019011933A/es unknown
- 2015-11-26 IL IL24280615A patent/IL242806B/en active IP Right Grant
-
2016
- 2016-09-05 HK HK16110542.4A patent/HK1222364A1/zh unknown
-
2019
- 2019-11-21 JP JP2019210232A patent/JP6843946B2/ja active Active
- 2019-12-18 HR HRP20192284TT patent/HRP20192284T1/hr unknown
-
2021
- 2021-03-22 US US17/207,811 patent/US20210205201A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2016520121A (ja) | 2016-07-11 |
KR102280377B1 (ko) | 2021-07-23 |
US20160101034A1 (en) | 2016-04-14 |
JP2020040973A (ja) | 2020-03-19 |
SG11201509636XA (en) | 2015-12-30 |
MX2019011933A (es) | 2020-08-31 |
CN108524320A (zh) | 2018-09-14 |
CA2912997A1 (en) | 2014-12-04 |
EP3003493B1 (en) | 2019-09-25 |
CN105407867A (zh) | 2016-03-16 |
HRP20192284T1 (hr) | 2020-03-06 |
US10980730B2 (en) | 2021-04-20 |
RU2015151047A (ru) | 2017-06-29 |
KR20160044437A (ko) | 2016-04-25 |
MX2015016262A (es) | 2016-07-19 |
ES2771048T3 (es) | 2020-07-06 |
IL242806B (en) | 2019-11-28 |
WO2014191995A3 (en) | 2015-03-19 |
BR112015029815B1 (pt) | 2020-06-30 |
DK3003493T3 (da) | 2020-01-13 |
EP3626310A1 (en) | 2020-03-25 |
JP6843946B2 (ja) | 2021-03-17 |
HK1222364A1 (zh) | 2017-06-30 |
EP3003493A2 (en) | 2016-04-13 |
WO2014191995A2 (en) | 2014-12-04 |
CA2912997C (en) | 2021-09-07 |
BR112015029815A2 (pt) | 2018-04-24 |
US20210205201A1 (en) | 2021-07-08 |
MX368498B (es) | 2019-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6843946B2 (ja) | 酵素系含有化粧品組成物 | |
JP5469870B2 (ja) | リグニンペルオキシオダーゼの製造方法 | |
Sunar et al. | Recent applications of enzymes in personal care products | |
JP3909290B2 (ja) | アルブチンとグルコシダーゼを有効成分として含有する美白剤 | |
KR101168741B1 (ko) | 리그닌 퍼옥시다제의 제조 방법 및 피부와 모발라이트닝에서의 이의 용도 | |
WO2012153336A9 (en) | Methods and device for lightening skin complexion | |
CN1121850C (zh) | 未发酵蜂蜜作为脱色剂的用途 | |
Huh et al. | Inhibitory effects of Phyllostachys bambusoides on melanin synthesis and tyrosinase activity in cultured human melanoma cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160323 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170526 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170526 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180706 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180927 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190107 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190409 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190709 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191023 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191121 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6622190 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |